Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8325647 | 0.86 | KMT2A (0.40) | PTGS2TP53KMT2AMEN1HSP90AA1 | |
| SCHEMBL8421338 | 0.79 | PTGS2 (0.48) | PTGS2TP53KMT2AMEN1HSP90AA1 | |
| SCHEMBL6670969 | 0.79 | KDM4E (0.45) | PTGS2TP53KMT2AMEN1HSP90AA1 | |
| SCHEMBL8326095 | 0.77 | KDM4E (0.44) | PTGS2TP53KMT2AMEN1HSP90AA1 | |
| Hydrochloric Acid SCHEMBL7645327 | 0.77 | KDM4E (0.44) | PTGS2TP53KMT2AMEN1HSP90AA1 | |
| SCHEMBL8531370 | 0.76 | PTGS2 (0.46) | PTGS2MAPK1TP53KMT2AMEN1 | |
| SCHEMBL7772904 | 0.76 | KMT2A (0.37) | PTGS2TP53KMT2AMEN1HSP90AA1 | |
| SCHEMBL9781255 | 0.75 | MAPK1 (0.43) | PTGS2MAPK1TP53KMT2AMEN1 | |
| SCHEMBL6716017 | 0.74 | L3MBTL1 (0.45) | PTGS2TP53KMT2AMEN1HSP90AA1 | |
| SCHEMBL8325511 | 0.74 | MAPK1 (0.39) | PTGS2MAPK1TP53KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985762-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-26 | — | — | US | disclosed |
| US-20110165120-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165120-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, PRSS3, PRSS2 | PTGS2 2947/4885MAPK1 971/4885TP53 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.